Hydrogel-nanoparticle delivery platform for LOCALized CAR-M immunotherapy

Objetivo

LOCAL-CAR is a Proof-of-Concept project aimed at validating a modular hydrogel-based platform for localized mRNA immunotherapy, targeting peritoneal tumor burden in ovarian and colorectal cancer models. Building on ERC-funded technologies – ABGel and aNP-mRNA – the project integrates these into a single ABGel-mRNA system for sustained intraperitoneal immunotherapy. The platform will generate HER2-CAR-expressing macrophages (CAR-M) directly within the peritoneal cavity, enabling local anti-HER2-tumor activity.
The project objectives are: (1) optimize ABGel-mRNA formulations encoding HER2-CAR constructs and screen their ability to generate functional CAR-M in vitro; (2) evaluate in vivo CAR‑M induction and therapeutic efficacy in mouse ovarian and colorectal cancer models; (3) develop IP strategy and expand patent portfolio; (4) conduct market analysis and engage stakeholders in the emerging in vivo CAR therapy landscape; and (5) disseminate findings and build strategic partnerships. Co-applicant BioTrip supports IP management, regulatory strategy, and commercialization. LOCAL-CAR addresses a critical unmet need in oncology and offers a scalable, biocompatible solution with broad translational potential in immunotherapy, autoimmune diseases, and vaccination.